Reverse Mergers & Low Float Plays

[Potse]

TGRP(.075)...Alchem's most recent contract......

It didn't receive a lot of investor attention at the time but CEO James Talton made another move/acquisition earlier this year that I think increased the overall attractiveness of the stock/business. He brought his other company (Alchem Laboratories) under the TGRP umbrella with relatively small dilution. Alchem is an interesting revenue-generating company involved in drug research/development and contract manufacturing. It has a history of securing or participating in government contracts and has done business with quite a few other biotech/pharma companies.

TGRP's subsidiary received a 7-year, almost $50M government contract around the end of July this year.

75N95024D00035 “Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products” 7-year IDIQ contract with NCATS-NIDA (8/1/24-7/31/31)

https://www.alchem.com/contracts